BLyS: The pivotal determinant of peripheral B cell selection and lifespan

Current Pharmaceutical Design

Volumn 9, Issue 23, 2003, Pages 1833-1847

  Smith, Susan Harless ^a   Cancro, Michael P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

B Lymphocytes; BLyS; Development; Homeostasis; TNF family

Indexed keywords

B LYMPHOCYTE ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN BCL 2; PROTEIN BLYS; RECEPTOR PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; BONE MARROW; CELL AGGREGATION; CELL CLONE; CELL KINETICS; CELL LOSS; CELL MATURATION; CELL SELECTION; CELL SPECIFICITY; CELL SURVIVAL; DRUG RESEARCH; DRUG TARGETING; HOMEOSTASIS; HUMORAL IMMUNITY; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; NONHUMAN; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STEADY STATE; STEM CELL;

ANIMALS; B-CELL ACTIVATION FACTOR RECEPTOR; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL DIVISION; CELL SURVIVAL; HUMANS; LIGANDS; MEMBRANE PROTEINS; MICE; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION;

EID: 0042976454     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033454405     Document Type: Review

References (163)

1. Mak TW, Yeh WC. Signaling for survival and apoptosis in the immune system. Arthritis Res 2002; 4 Suppl 3: S243-52.
2. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104(4): 487-501.
3. Siegel RM, Lenardo MJ. To B or not to B: TNF family signaling in lymphocytes. Nat Immunol 2001; 2(7): 577-8.
4. Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: A Tutorial on B Cell Survival. Annu Rev Immunol 2002.
5. Do RK, Chen-Kiang S. Mechanism of BLyS action in B cell immunity. Cytokine Growth Factor Rev 2002; 13(1): 19-25.
6. Waldschmidt TJ, Noelle RJ. Immunology. Long live the mature B cell - a baffling mystery resolved. Science 2001; 293(5537): 2012-3.
7. MacLennan I, Vinuesa C. Dendritic cells, BAFF, and APRIL: innate players in adaptive antibody responses. Immunity 2002; 17(3): 235-8.
8. Moore PA, Belvedere O, Orr A, Piero K, LaFleur DW, Feng P, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285(5425): 260-3.
9. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190(11): 1697-710.
10. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, et al. Taci-Ig neutralizes molecules critical for B cell development and autoimmune disease: Impaired B cell maturation in mice lacking BLyS. Immunity 2001; 15(2): 289-302.
11. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001;293:2111-14.
12. Lentz VM, Cancro MP, Nashold FE, Hayes CE. Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the A/WySnJ mouse. Journal of Immunology 1996; 157: 598-606.
13. Lentz VM, Hayes CE, Cancro MP. Bcmd decreases the life span of B-2 but not B-1 cells in A/WySnJ mice. J Immunol 1998; 160(8): 3743-7.
14. Stohl W, Cheema GS, Briggs WS, Xu D, Sosnovtseva S, Roschke V, et al. B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients. Clin Immunol 2002; 104(2): 115-22.
15. Stohl W. B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases. Curr Rheumatol Rep 2002; 4(4): 345-50.
16. Mackay F, Mackay CR. The role of BAFF in B-cell maturation, T-cell activation and autoimmunity. Trends Immunol 2002; 23(3): 113-5.
17. Kalled SL. BAFF: a novel therapeutic target for autoimmunity. Curr Opin Investig Drugs 2002; 3(7): 1005-10.
18. Stohl W. Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein. Curr Opin Rheumatol 2002; 14(5): 522-8.
19. Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2002; 3(7): 424-9.
20. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44(6): 1313-9.
21. Groom J, Kalled SL, Cutler AH, Olson C. Woodcock SA. Schneider P, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002; 109(1): 59-68.
22. Laabi Y, Strasser A. Immunology. Lymphocyte survival -ignorance is BLys. Science 2000; 289(5481): 883-4.
23. Khare SD, Hsu H. The role of TALL-1 and APRIL in immune regulation. Trends Immunol 2001; 22(2): 61-3.
24. Vaux DL. The buzz about BAFF. J Clin Invest 2002; 109(1): 17-8.
25. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002; 2(7):465-75.
26. Macpherson AJ, Lamarre A. BLySsful interactions between DCs and B cells. Nat Immunol 2002; 3(9): 798-800.
27. Rolink AG, Melchers F. BAFFled B cells survive and thrive: roles of BAFF in B-cell development. Curr Opin Immunol 2002; 14(2): 266-75.
28. Defrance T, Casamayor-Palleja M, Krammer PH. The life and death of a B cell. Adv Cancer Res 2002; 86: 195-225.
29. Ambrose CM. Baff-R. J Biol Regul Homeost Agents 2002; 16(3): 211-3.
30. Pound J. A key role for BAFF in maintaining peripheral B cells. Trends Immunol 2001; 22(12): 659.
31. Osmond DG. Population dynamics of bone marrow B lymphocytes. Immunol Rev 1986; 93: 103-124.
32. Osmond DG. B cell development in the bone marrow. Semin Immunol 1990; 2: 173-180.
33. Osmond DG, Rolink A, Melchers F. Murine B lymphopoiesis: towards a unified model. Immunol Today 1998; 19(2): 65-8.
34. Hardy RR, Hayakawa K. B-lineage differentiation stages resolved by multiparameter flow cytometry. Ann N Y Acad Sci 1995; 764: 19-24.
35. Allman D, Li J, Hardy RR. Commitment to the B lymphoid lineage occurs before DH-JH recombination. J Exp Med. 1999 Feb 15; 189(4): 735-740.
36. Hardy RR CC, Shinton SA, Kemp JD, Hayakawa K. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med 1991 May 1; 173(5): 1213-25.
37. Hardy RR. B cell ontogeny and B cell subsets. Curr Opin Immunol 1989; 2(2): 189-98.
38. Li Y-S, Wasserman R, Hayakawa K, Hardy RR. Identification of the earliest B lineage stage in mouse bone marrow. Immunity 1996; 5: 527-535.
39. Miller JP, Izon D, DeMuth W, Gerstein R, Bhandoola A, Allman D. The earliest step in B lineage differentiation from common lymphoid progenitors is critically dependent upon interleukin 7. J Exp Med 2002; 196(5): 705-11.
40. hi and exhibit unique signaling characteristics. J Immunol 1992; 149(8): 2533-2540.
41. Allman DM, Ferguson SE, Lentz VM, Cancro MP. Peripheral B cell maturation. II. Heat-stable antigen(hi) splenic B cells are an immature developmental intermediate in the production of long-lived marrow-derived B cells. J Immunol 1993; 151(9): 4431-4444.
42. Cancro MP, Allman DM, Hayes CE, Lentz VM, Fields RG, Sah AP, et al. B Cell Maturation and Selection at the Marrow-Periphery Interface. Immunologic Research 1998; 17: 3-11.
43. Rolink AG, Andersson J, Melchers F. Characterization of immature B cells by a novel monoclonal antibody, by turnover and by mitogen reactivity. Eur J Immunol 1998; 28(11): 3738-48.
44. Carsetti R, Kohler G, Lamers MC. Transitional B cells are the target of negative selection in the B cell compartment. J Exp Med 1995; 181(6): 2129-2140.
45. Loder F, Mutschler B, Ray RJ, Paige CJ, Sideras P, Torres R, et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med 1999; 190(1): 75-89.
46. Allman D, Lindsley RC, DeMuth W, Rudd K, Shinton SA, Hardy RR. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol 2001; 167(12): 6834-6840.
47. Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002; 168(12): 5993-6.
48. Martin F, Kearney JF. Marginal-zone B cells. Nat Rev Immunol 2002; 2(5): 323-35.
49. Won WJ, Kearney JF. CD9 is a unique marker for marginal zone B cells, B1 cells, and plasma cells in mice. J Immunol 2002; 168(11): 5605-11.
50. Hardy RR, Li YS, Hayakawa K. Distinctive developmental origins and specificities of the CD5+ B-cell subset. Semin Immunol 1996; 8(1): 37-44.
51. Berland R, Wortis HH. Origins and functions of B-1 cells with notes on the role of CD5. Annu Rev Immunol 2002; 20: 253-300.
52. Hayakawa K, Li YS, Wasserman R, Sander S, Shinton S, Hardy RR. B lymphocyte developmental lineages. Ann N Y Acad Sci 1997; 815: 15-29.
53. Martin F, Kearney JF. Selection in the mature B cell repertoire. Curr Top Microbiol Immunol 2000; 252: 97-105.
54. Kearney JF, Won WJ, Benedict C, Moratz C, Zimmer P, Oliver A, et al. B cell development in mice. Int Rev Immunol 1997; 15(3-4): 207-41.
55. Martin F, Kearney JF. B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol 2001; 13(2): 195-201.
56. Cariappa A, Pillai S. Antigen-dependent B-cell development. Curr Opin Immunol 2002; 14(2): 241-9.
57. Tyler RW, Everett NB. Radioautographic study of cellular migration using parabiotic rats. Blood 1972; 39(2): 249-66.
58. Yoshida Y, Osmond DG. Identity and proliferation of small lymphocyte precursors in cultures of lymphocyte-rich fractions of guinea pig bone marrow. Blood 1971; 37(1): 73-86.
59. Osmond DG, Park YH. B lymphocyte progenitors in mouse bone marrow. Int Rev Immunol 1987; 2: 241-260.
60. Sprent J, Basten A. Circulating T and B lymphocytes of the mouse. II. Lifespan. Cell Immunol 1973; 7: 40.
61. Nossal G, Pike B. Evidence for the clonal abortion theory of B-lymphocyte tolerance. J Exp Med 1975; 141: 904-917.
62. Nossal GJV. Cellular mechanisms of immunological tolerance. Ann Rev Immunol 1983; 1: 33-62.
63. Nossal GJ. B lymphocyte physiology: the beginning and the end. Ciba Found Symp 1997; 204: 220-30; discussion 230-1.
64. Goodnow CC, Crosbie J, Jorgensen H, Brink RA, Basten A. Induction of self-tolerance in mature peripheral B lymphocytes. Nature 1989; 342(Nov. 23): 385-391.
65. Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature (Lond.) 1989; 337: 562-566.
66. Nemazee D, Russell D, Arnold B, Haemmerling G, Allison J, Miller JFAP, et al. Clonal deletion of autospecific B lymphocytes. Immunological Reviews 1991; 122: 117-132.
67. Goodnow CC, Cyster JG, Hartley SB, Bell SE, Cooke MP, Healy JI, et al. Self-tolerance checkpoints in B lymphocyte Development. Advances in Immunology 1995; 59: 279-368.
68. Waldschmidt T, Vitetta E. The use of haptenated-immunoglobulin molecules to induce tolerance in B cells from neonatal mice. J Immunol 1985; 134(3): 1436-41.
69. Metcalf E, Klinman N. In vitro tolerance induction of neonatal murine B cells. J Exp Med 1976; 143: 1327-1340.
70. Metcalf E, Klinman N. In vitro tolerance induction of bone marrow cells: a marker for B cell maturation. J Immunol 1977; 118(6): 2111-6.
71. Cambier J, Kettman J, Vitetta E, Uhr J. Differential susceptibility of neonatal and adult murine spleen cells to in vitro induction of B-cell tolerance. J Exp Med 1976; 144: 293-297.
72. Hartley SB, Cooke MP, Fulcher DA, Harris A, Cory S, Basten A, et al. Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell 1993; 72(3): 325-35.
73. Goodnow CC, Crosbie J, Adelstein S, Lavoie TB, Smith-Gill SJ, Brink RA, et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 1988; 334(Aug 25): 676-682.
74. Fulcher DA, Basten A. Reduced life span of anergic self-reactive B cells in a double-transgenic model. J Exp Med 1994; 179: 125-134.
75. Fulcher DA, Basten A. Whither the anergic B-cell? Autoimmunity 1994; 19(2): 135-40.
76. Mandik-Nayak L, Bui A, Noorchashm H, Eaton A, Erikson J. Regulation of anti-double-stranded DNA B cells in nonautoimmune mice: localization to the T-B interface of the splenic follicle. J Exp Med 1997; 186: 1257-1267.
77. Russell D, Dembic Z, Morahan G, Miller J, Burki K, Nemazee D. Peripheral deletion of self-reactive B cells. Nature 1991: 354(6351): 308-311.
78. Nemazee D, Weigert M. Revising B cell receptors. J Exp Med 2000 191(11): 1813-7.
79. Gay D. Saunders T, Camper S, Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J Exp Med 1993; 177(4): 999-1008.
80. Prak EL, Trounstine M, Huszar D, Weigert M. Light chain editing in kappa-deficient animals: a potential mechanism of B cell tolerance. J Exp Med 1994; 180(5): 1805-15.
81. Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bone marrow B cells. J Exp Med 1993; 177(4): 1009-20.
82. Gu H, Tarlinton D, Muller W, Rajewsky K, Forster I. Most peripheral B cells in mice are ligand selected. J Exp Med 1991; 173: 1357-71.
83. Levine MH, Haberman AM, Sant'Angelo DB, Hannum LG, Cancro MP, Janeway CA, Jr., et al. A B-cell receptor-specific selection step governs immature to mature B cell differentiation. Proc Natl Acad Sci USA 2000; 97(6): 2743-2748.
84. Agenes F, Rosado MM, Freitas AA. Independent homeostatic regulation of B cell compartments. Eur J Immunol 1997; 27(7): 1801-1807.
85. Agenes F, Freitas AA. Transfer of small resting B cells into immunodeficient hosts results in the selection of a self-renewing activated B cell population. J Exp Med 1999; 189(2): 319-30.
86. Agenes F, Rosado MM, Freitas AA. Considerations on B cell homeostasis. Curr Top Microbiol Immunol 2000; 252: 68-75.
87. Agenes F, Rosado MM, Freitas AA. peripheral B cell survival. Cell Mol Life Sci 2000; 57(8-9): 1220-8.
88. Rosado MM, Freitas AA. The role of the B cell receptor V region in peripheral B cell survival. Eur J Immunol 1998; 28(9): 2685-93.
89. Turner M, Gulbranson-Judge A, Quinn ME, Walters AE, MacLennan IC, Tybulewicz VL. Syk tyrosine kinase is required for the positive selection of immature B cells into the recirculating B cell pool. Journal of Experimental Medicine 1997; 186(12): 2013-21.
90. Cyster JG, Hartley SB, Goodnow CC. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 1994; 371: 389-395.
91. Cyster JG, Healy JI, Kishihara K, Mak TW, Thomas ML, Goodnow CC. Regulation of B-lymphocyte negative and positive selection by tyrosine phosphatase CD45. Nature 1996; 381: 325-328.
92. Cyster JG. Signaling thresholds and interclonal competition in preimmune B-cell selection. Immunol Rev 1997; 156: 87-101.
93. Fulop G, Gordon J, Osmond DG. Regulation or lymphocyte production in the bone marrow. I. Turnover of small lymphocytes in mice depleted of B lymphocytes by treatment with anti-IgM antibodies. J Immunol 1983; 130(2): 644-8.
94. Osmond DG, Gordon J. Characterization of small lymphocytes in the bone marrow of mice after prolonged treatment with anti-IgM antibodies. Cell Immunol 1979; 42(1): 188-93.
95. Osmond DG. The turnover of B cell populations. Immunol. Today 1993; 14: 34-37.
96. Sprent J. Migration and lifespan of lymphocytes. In: Roelants FLaGE, editor. B and T cells in immune recognition. London: John Wiley and Sons; 1977. p. 59-82.
97. Lain KP, Kulin R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997; 90(6): 1073-83.
98. Bannish G, Fuentes-Panana EM, Cambier JC, Pear WS, Monroe JG. Ligand-independent signaling functions for the B lymphocyte antigen receptor and their role in positive selection during B lymphopoiesis. J Exp Med 2001; 194(11): 1583-96.
99. Freitas AA. Rosado MM, Viale AC, Grandien A. The role of cellular competition in B cell survival and selection of B cell repertoires. Eur J Immunol 1995; 25(6): 1729-38.
100. McLean AR, Rosado MM, Agenes F, Vasconcellos R, Freitas AA. Resource competition as a mechanism for B cell homeostasis. Proc Natl Acad Sci USA 1997; 94(11): 5792-7.
101. De Boer RJ, Freitas AA, Perelson AS. Resource competition determines selection or B cell repertoires. J Theor Biol 2001; 212(3): 333-43.
102. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002; 27(1): 19-26.
103. Smith CA FT, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994 Mar 25; 76(6): 959-62.
104. Shu HB, Hu WH, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 1999; 65(5): 680-3.
105. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404(6781): 995-9.
106. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189(11): 1747-56.
107. Yu G, Boone T, Delaney J, Hawkins N, Kelley M, Ramakrishnan M, et al. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 2000; 1(3): 252-6.
108. Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998; 188(6): 1185-90.
109. Rennert P, Schneider P. Cachero TG, Thompson J. Trabach L, Hertig S, et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med 2000; 192(11): 1677-84.
110. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A. Casali P, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002.
111. Stein JV, Lopez-Fraga M, Elustondo FA, Carvalho-Pinto CE, Rodriguez D, Gomez-Caro R, et al. APRIL modulates B and T cell immunity. J Clin Invest 2002; 109(12): 1587-98.
112. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, Migone TS, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001; 97(1): 198-204.
113. Oren DA, Li Y, Volovik Y, Morris TS, Dharia C, Das K, et al. Structural basis of BLyS receptor recognition. Nat Struct Biol 2002; 9(4): 288-92.
114. Liu Y, Xu L, Opalka N, Kappler J, Shu HB, Zhang G. Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell 2002; 108(3): 383-94.
115. Karpusas M, Cachero TG, Qian F, Boriack-Sjodin A, Mullen C, Strauch K, et al. Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J Mol Biol 2002; 315(5): 1145-54.
116. Madry C, Laabi Y, Callebaut I, Roussel J, Hatzoglou A, Le Coniat M, et al. The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily. Int Immunol 1998; 10(11): 1693-702.
117. von Bulow GU, Bram RJ. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997; 278(5335): 138-41.
118. Yan M, Brady JR, Chan B, Lee WP, Hsu B, Harless S, et al. Identification of a novel receptor for B lymphocyte stimulator (BLyS) that is mutated in a mouse strain with severe B cell deficiency. Current Biology 2001: 11: 1547-1552.
119. Gras MP, Laabi Y, Linares-Cruz G, Blondel MO, Rigaut JP, Brouet JC, et al. BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes. Int Immunol 1995; 7(7): 1093-106.
120. Laabi Y, Gras MP, Brouet JC, Berger R, Larsen CJ, Tsapis A. The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res 1994; 22(7): 1147-54.
121. Thompson JS, Schneider P, Kalled SL, Wang L, Lefevre EA, Cachero TG, et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med 2000; 192(1): 129-35.
122. Hatzoglou A, Roussel J. Bourgeade MF, Rogier E, Madry C, Inoue J, et al. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol 2000; 165(3): 1322-30.
123. Xu S, Lam KP. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol 2001; 21(12): 4067-74.
124. Harless SM, Lentz VM, San AP, Hsu BL, Clise-Dwyer K, Hilbert DM, et al. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr Biol 2001; 11(24): 1986-9.
125. von Bulow GU, Russell H, Copeland NG, Gilbert DJ, Jenkins NA, Bram RJ. Molecular cloning and functional characterization of murine transmembrane activator and CAML interactor (TACI) with chromosomal localization in human and mouse. Mamm Genome 2000; 11(8): 628-32.
126. Xia X, Treanor J, Senaldi G, Khare S, Boone T, Kelley M, et al. TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med 2000 Jul 3; 192(1): 137-43.
127. Yan M, Marsters SA, Grewal IS, Wang H, Ashkenazi A, Dixit VM. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol 2000; 1(1): 37-41.
128. Xia XZ, Treanor J, Senaldi G, Khare SD, Boone T, Kelley M, et al. TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med 2000; 192(1): 137-43.
129. Yan M, Brady JR, Chan B, Lee WP, Hsu B, Harless S, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol 2001; 11(19): 1547-52.
130. Thompson JS, Bixler SA, Qian F, Vora K. Scott ML, Cachero TG, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001; 293(5537):2108-11.
131. Kayagaki N, Yan M, Seshasayee D. Wang H, Lee W, French DM, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002; 17(4): 515-24.
132. Khare SD, Sarosi I, Xia XZ, McCabe S, Miner K, Solovyev I, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000; 97(7): 3370-5.
133. Miller DJ, Hayes CF. Phenotypic and genetic characterization of a unique B lymphocyte deficiency in strain A/WySnJ mice. European Journal of Immunology 1991; 21: 1123.
134. Miller DJ, Hanson KD, Carman JA, Hayes CE. A single autosomal gene defect severely limits IgG but not IgM responses in B lymphocyte-deficient A/WySnJ mice. European Journal of Immunology 1992; 22: 373.
135. Yan M, Wang H, Chan B, Roose-Girma M, Erickson S, Baker T, et al. Activation and accumulation of B cells in TACI-deficient mice. Nature Immunology 2001; 2(7): 638-643.
136. Rolink AG, Tschopp J, Schneider P, Melchers F. BAFF is a survival and maturation factor for mouse B cells. Eur J Immunol 2002; 32(7): 2004-10.
137. Sprent J, Tough DF. Lymphocyte life-span and memory. Science 1994: 265(5177): 1395-400.
138. Lentz VM. Bcmd Governs Recruitment of Newly Formed B-2 Cells into the Stable Peripheral B Cell Pool. Doctoral Thesis, University of Pennsylvania 1997.
139. Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000; 192(7): 953-64.
140. Adams JM, Huang, D.C., Puthalakath, H., Bouillet, P., Vairo, G., Moriishi, K., Hausmann, G., O'Reilly L., Newton, K., Ogilvy S., Bath M.L., Print C.G., Harris, A.W., Strasser A,, S. C. Control of apoptosis in hematopoietic cells by the Bcl-2 family of proteins. Cold Spring Harb Symp Quant Biol 1999; 64: 351-358.
141. Cory S. Regulation of lymphocyte survival by the bcl-2 gene family. Ann Rev Immunol 1995; 13: 513-543.
142. Korsmeyer SJ. Regulators of cell death. Trends Genetics 1995; 11: 101-105.
143. Strasser A, O'Connor L, Huang DC, O'Reilly LA, Stanley ML, Bath ML, et al. Lessons from bcl-2 transgenic mice for immunology, cancer biology and cell death research. Behring Institute Mitteilungen 1996(97): 101-17.
144. Gibson LF, Piktel D, Narayanan R, Nunez G, Landreth KS. Stromal cells regulate bcl-2 and bax expression in pro-B cells. Experimental Hematology 1996; 24(5): 628-37.
145. Grillot DA, Merino R, Pena JC, Fanslow WC, Finkelman FD, Thompson CB, et al. bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. Journal of Experimental Medicine 1996; 183(2): 381-91.
146. Li YS, Hayakawa K, Hardy RR. The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver. J Exp Med 1993; 178(3): 951-960.
147. Liu YJ, Mason DY, Johnson GD, Abbot S, Gregory CD, Hardie DL, et al. Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis. Eur J Immunol 1991; 21(8): 1905-1910.
148. Merino R, Ding L, Veis D, Korsmeyer S, Nunez G. Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J 1994; 13(3): 683-91.
149. Nunez G, Merino R, Grillot D, Gonzalez-Garcia M. Bcl-2 and Bcl-x: regulatory switches for lymphoid death and survival. Immunol Today 1994; 15(12): 582-8.
150. Tomayko MM, Cancro MP. Long-lived B cells are distinguished by elevated expression of A1. J Immunol 1998; 160: 107-111.
151. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57: 79-88.
152. O'Reilly LA, Harris AW, Tarlinton DM, Corcoran LM, Strasser A. Expression of a bcl-2 transgene reduces proliferation and slows turnover of developing B lymphocytes in vivo. Journal of Immunology 1997; 159(5): 2301-11.
153. Strasser A, Harris AW, Corcoran LM, Cory S. Bcl-2 expression promotes B- but not T-lymphoid development in scid mice. Nature (Lond.) 1994; 368(6470): 457-60.
154. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S, et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1991; 88(19): 8661-5.
155. Clise-Dwyer K, Amanna IJ, Duzeski JL, Nashold FE, Hayes CE. Genetic studies of B-lymphocyte deficiency and mastocytosis in strain A/WySnJ mice. Immunogenetics 2001; 53(9): 729-35.
156. Smith SH, Cancro MP. Cutting Edge. BcR signals regulate BlyS receptor levels in mature B cells and their immediate progenitors. J Immunol 2003; (in press).
157. Nardelli B, Moore PA, Li Y, Hilbert DM. B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases. Leuk Lymphoma 2002; 43(7): 1367-73.
158. Haseltine WA. Genomics and drug discovery. J Am Acad Dermatol 2001; 45(3): 473-5.
159. Mukhopadhyay A, Ni J, Zhai Y, Yu GL, Aggarwal BB. Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J Biol Chem 1999; 274(23): 15978-81.
160. Tribouley C, Wallroth M, Chan V, Paliard X, Fang E, Lamson G, et al. Characterization of a new member of the TNF family expressed on antigen presenting cells. Biol Chem 1999; 380(12): 1443-7.
161. Alvarez D, Wiley RE, Jordana M. Cytokine therapeutics for asthma: an appraisal of current evidence and future prospects. Curr Pharm Des 2001; 7(11): 1059-81.
162. Gordeladze JO, Reseland JE, Drevon CA. Pharmacological interference with transcriptional control of osteoblasts: a possible role for leptin and fatty acids in maintaining bone strength and body lean mass. Curr Pharm Des 2001; 7(4): 275-90.
163. Iyer S, Lahana R, Buelow R. Rational design and development of RDP58. Curr Pharm Des 2002; 8(24): 2217-29.